-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 29, Novavax and SII announced that the Drug Administration of India (DCGI) has granted an emergency use authorization (EUA) to Novavax for the recombinant nanoparticle protein new coronary pneumonia vaccine based on Matrix-M™ adjuvant
Since the refrigeration standard for storing vaccines is 2 degrees Celsius to 8 degrees Celsius, the existing vaccine supply chain can be used for transportation and storage, thereby increasing the possibility of providing vaccines to remote areas
The Novavax/SII vaccine has recently received emergency use authorization (EUA) in Indonesia and the Philippines, and has been included in the World Health Organization (WHO) Emergency Use List (EUL)
Original English: https://ir.
https://ir.
novavax.
com/2021-12-28-Novavax-and-Serum-Institute-of-India-Receive-Emergency-Use-Authorization-for-COVID-19-Vaccine-in-India